The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trialsJonathan I. Silverberg, Jonathan Zalevsky, David Rosmarin et al.|Nature Communications|2024Cited by 37
NKTR-255 Vs Placebo to Enhance Complete Responses and Durability Following CD19-Directed CAR-T Therapy in Patients with Relapsed/ Refractory (R/R) Large B-Cell Lymphoma (LBCL)Sairah Ahmed, Joseph P. McGuirk, John F. DiPersio et al.|Blood|2024Cited by 3
NKTR-255 Vs Placebo to Enhance Complete Responses and Durability Following CD19-Directed CAR-T Therapy in Patients with Relapsed/ Refractory (R/R) Large B-Cell Lymphoma (LBCL)Sairah Ahmed, Joseph P. McGuirk, James Essell et al.|Transplantation and Cellular Therapy|2025Cited by 3
729 - A phase 2b, randomized, double-blinded, parallel-group, placebo-controlled, international, multicenter, study to evaluate the efficacy and safety of rezpegaldesleukin in adults with moderate-to-severe atopic dermatitisMelinda Gooderham, David Rosmarin, Charles Lynde et al.|British Journal of Dermatology|2024Cited by 2
REZPEGALDESLEUKIN, NOVEL TREG-INDUCING THERAPY, DEMONSTRATES EFFICACY IN ATOPIC DERMATITIS AND ASTHMA IN PHASE 2B TRIALJonathan Corren, David Rosmarin, P. Lio et al.|Annals of Allergy Asthma & Immunology|2025Cited by 1